Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group

Robert Dreicer, Bruce Roth, George Wilding

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Advanced transitional cell carcinoma of the urothelium is an aggressive malignancy characterized by a median survival period of less than 1 year. Although this disease is moderately chemotherapy-sensitive, to the authors' knowledge the impact of therapy reported to date on survival has been minimal. The authors presented an overview of the results from a series of clinical trials conducted over a 25-year period under the auspices of the Eastern Cooperative Oncology Group. They reviewed a series of antineoplastic agents identified by these studies with activity in advanced urothelial cancer and discussed current and future investigational goals and directions.

Original languageEnglish
Pages (from-to)2109-2114
Number of pages6
JournalCancer
Volume97
Issue number8 SUPPL.
DOIs
StatePublished - Apr 15 2003

Keywords

  • Antineoplastic agents
  • Bladder cancer
  • Chemotherapy
  • Clinical trials

Fingerprint

Dive into the research topics of 'Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group'. Together they form a unique fingerprint.

Cite this